Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2017-05-17 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
ATL1103 Update 2 pages 46.4KB
Regulatory Filings Classification · 95% confidence The document is an update from Antisense Therapeutics Limited regarding the ATL1103 Phase II clinical trial data submission for publication and ongoing partnering discussions. It provides scientific and development progress information but does not contain financial data, regulatory filings, or formal report content such as annual or quarterly financial results. It is a corporate update focused on clinical trial progress and partnering status, which fits best under a general regulatory announcement category rather than a financial or governance report. The document length is about 4975 characters, and it is not a report publication announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate updates that do not fit other categories.
2017-05-17 English
Appendix 4C - quarterly 5 pages 100.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed financial data including cash flows from operating, investing, and financing activities for a specific quarter ending 31 March 2017. It includes actual financial figures, estimated cash outflows for the next quarter, and a compliance statement signed by the company secretary. The presence of substantive financial data and the quarterly period covered clearly indicate this is a quarterly financial report. The document is 8,334 characters long, which is sufficient to be a full report rather than a brief announcement. The reference to Listing Rule 4.7B and the format aligns with Australian ASX quarterly reporting requirements. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2017
2017-04-26 English
ATL1102 for MS Phase IIb Investigational New Drug Submission 1
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 24 April 2017 regarding the initiation of the submission process for an Investigational New Drug (IND) application for ATL1102 for Multiple Sclerosis Phase IIb trial. It describes the clinical trial plans, regulatory submission process, and background information about the company and the drug. There are no financial statements, earnings data, or detailed financial analysis present. The document is informational about a regulatory submission and clinical trial progress rather than a financial report or formal regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a call transcript, management change, or capital update. It is a regulatory announcement about a drug development milestone. Given the content and length (4652 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-04-23 English
Market and Technology Update 2 pages 364.8KB
Capital/Financing Update Classification · 85% confidence The document is titled 'Market and Technology Update' and provides detailed information about the company's late-stage drug pipeline, market context, recent industry transactions, and technology collaborations. It discusses clinical progress, regulatory approvals of related drugs by partners, and upcoming trial submissions. The content is an update on business and technology developments rather than a formal financial report or regulatory filing. It does not contain financial statements, earnings data, or voting results. The document length is 6586 characters, which is substantial but the content is clearly an operational and market update. This fits best with the Capital/Financing Update (CAP) category, as it relates to business development and pipeline progress relevant to company valuation and investor interest, but not a formal earnings release or annual/interim report.
2017-03-23 English
Change of Director's Interest Notice (RM) 2 pages 22.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including dates, number of shares/options held before and after the change, and nature of the transactions. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of insider share transactions by a company director, consistent with insider trading disclosure requirements. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is under 5,000 characters and contains detailed transaction data, not just an announcement or certification, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2017-02-28 English
Half Year Accounts 25 pages 372.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Antisense Therapeutics Limited Appendix 4D For the Half-year ended 31 December 2016' and contains detailed financial results, including revenues, loss after tax, net tangible assets per share, and earnings per share for the half-year period ending 31 December 2016. It includes a Directors' report, review of operations, auditor's review report, and detailed financial statements such as profit or loss, financial position, changes in equity, cash flows, and notes to the financial statements. The document is comprehensive and covers a period shorter than a full fiscal year (half-year). It is not merely an announcement or a brief summary but contains substantive financial data and analysis. The presence of an auditor's review report and detailed financial statements confirms it is an interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-02-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.